Difficulty: Medium
Average Score: 76%
Practice
A nurse is caring for a client who is about to begin therapy with recombinant factor IX to treat hemophilia B. The client asks the nurse about the risk of disease transmission with recombinant factor IX as compared with plasma derived factor IX. The nurse should explain that the recombinant factor IX practically eliminates the risk for which of the following?
Correct answer
C
Rationale
In this scenario, the correct answer is C) Creutzfeldt-Jakob disease. The nurse should explain to the client that recombinant factor IX practically eliminates the risk of Creutzfeldt-Jakob disease compared to plasma-derived factor IX. Creutzfeldt-Jakob disease is a rare, degenerative, fatal brain disorder that is associated with prion transmission, which can potentially be present in plasma-derived products due to the nature of how they are processed.
Option A) HIV and option B) Cytomegalovirus are also risks associated with plasma-derived products due to the potential for contamination from blood products. However, with the advancements in recombinant technology, the risk of HIV and Cytomegalovirus transmission is also greatly reduced with recombinant factor IX.
Option D) Anaphylaxis is a possible adverse reaction to factor IX therapy, but it is not specifically related to the source of the factor IX (recombinant or plasma-derived).
Educationally, it is important for nurses to understand the differences between recombinant and plasma-derived products in hemophilia treatment to provide accurate information to clients and ensure safe and effective care. This knowledge empowers nurses to educate clients on the benefits and risks associated with different treatment options, promoting informed decision-making and optimal outcomes for clients with hemophilia.
Option A) HIV and option B) Cytomegalovirus are also risks associated with plasma-derived products due to the potential for contamination from blood products. However, with the advancements in recombinant technology, the risk of HIV and Cytomegalovirus transmission is also greatly reduced with recombinant factor IX.
Option D) Anaphylaxis is a possible adverse reaction to factor IX therapy, but it is not specifically related to the source of the factor IX (recombinant or plasma-derived).
Educationally, it is important for nurses to understand the differences between recombinant and plasma-derived products in hemophilia treatment to provide accurate information to clients and ensure safe and effective care. This knowledge empowers nurses to educate clients on the benefits and risks associated with different treatment options, promoting informed decision-making and optimal outcomes for clients with hemophilia.